Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Dramatic decline in risk for heart attacks among HIV-positive Kaiser Permanente members

Previously reported increased risk of heart attacks among HIV-positive individuals has been largely reversed in recent years for Kaiser Permanente's California patients, according to a study published in the current online issue of Clinical Infectious Diseases. The adjusted risk ratio for heart attacks among HIV-positive study participants went from an 80 percent increased risk in 1996 to no increased risk in 2010-2011. Reported first on Aidsmap at http://www.aidsmap.com/Heart-attack-risk-in-people-with-HIV-may-be-falling-but-not-in-women/page/2834402/ .

Published
19 January 2015
From
Eurekalert
Drug Resistance, While Rare, Can Occur After Contracting HIV on PrEP

For the first time, a study has shown that, although rare, resistance to Truvada can develop if someone contracts HIV while taking the drug as PrEP.

Published
16 January 2015
From
AIDSMeds
Hepatitis C drug delayed by NHS due to high cost

The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.

Published
16 January 2015
From
The Guardian
Janssen launches HIV combo Rezolsta in UK

Johnson & Johnson unit Janssen has launched its once-daily, fixed-dose HIV combination therapy Rezolsta in the UK.

 Rezolsta combines the company’s big-selling HIV therapy Prezista (darunavir) and Gilead Science’s Tybost (cobicistat).

Published
15 January 2015
From
Pharma Times
Dolutegravir and Truimeq approved in England: London guidelines updated

On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

Published
14 January 2015
From
HIV i-Base
New HIV Gene Therapy Shows Promise in Mice

Researchers were able to replicate the functional cure of HIV that was seen in the "Berlin patient" in a mouse model, according to a study conducted at the University of California, Davis.

Published
14 January 2015
From
The Body Pro
Study uncovers new ground about when to start HIV therapy

A major question that has recurred since the availability of potent combination anti-HIV therapy (commonly called ART or HAART) is when this therapy should be initiated to ensure the optimal health of HIV-positive people. New research has revealed that early therapy may be highly beneficial.

Published
13 January 2015
From
CATIE
Dolutegravir/abacavir/lamivudine: considerable added benefit for treatment-naive adults with HIV

Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. The Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.

Published
12 January 2015
From
The Institute for Quality and Efficiency in Health Care
Argos tanks as its HIV immunotherapy flunks Phase II

The treatment, AGS-004, is a personalized immunotherapy designed to train patients' T cells to better attack HIV. In a placebo-controlled Phase IIb trial, AGS-004 missed its primary endpoint of significantly lowering viral load among chronically infected patients.

Published
12 January 2015
From
FierceBiotech
I Am the Berlin Patient: A Personal Reflection

My name is Timothy Ray Brown and I am the first person in the world to be cured of HIV.

Published
08 January 2015
From
AIDS Research and Human Retroviruses

Filter by country